<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32667139</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1582-4934</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>17</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of cellular and molecular medicine</Title><ISOAbbreviation>J Cell Mol Med</ISOAbbreviation></Journal><ArticleTitle>Molecular and behavioural abnormalities in the FUS-tg mice mimic frontotemporal lobar degeneration: Effects of old and new anti-inflammatory therapies.</ArticleTitle><Pagination><StartPage>10251</StartPage><EndPage>10257</EndPage><MedlinePgn>10251-10257</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.15628</ELocationID><Abstract><AbstractText>Genetic mutations in FUS, a DNA/RNA-binding protein, are associated with inherited forms of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). A novel transgenic FUS[1-359]-tg mouse line recapitulates core hallmarks of human ALS in the spinal cord, including neuroinflammation and neurodegeneration, ensuing muscle atrophy and paralysis, as well as brain pathomorphological signs of FTLD. However, a question whether FUS[1-359]-tg mouse displays behavioural and brain pro-inflammatory changes characteristic for the FTLD syndrome was not addressed. Here, we studied emotional, social and cognitive behaviours, brain markers of inflammation and plasticity of pre-symptomatic FUS[1-359]-tg male mice, a potential FTLD model. These animals displayed aberrant behaviours and altered brain expression of inflammatory markers and related pathways that are reminiscent to the FTLD-like syndrome. FTLD-related behavioural and molecular Journal of Cellular and Molecular Medicine features were studied in the pre-symptomatic FUS[1-359]-tg mice that received standard or new ALS treatments, which have been reported to counteract the ALS-like syndrome in the mutants. We used anti-ALS drug riluzole (8&#xa0;mg/kg/d), or anti-inflammatory drug, a selective blocker of cyclooxygenase-2 (celecoxib, 30&#xa0;mg/kg/d) for 3&#xa0;weeks, or a single intracerebroventricular (i.c.v.) infusion of human stem cells (Neuro-Cells, 500&#xa0;000-CD34<sup>+</sup> ), which showed anti-inflammatory properties. Signs of elevated anxiety, depressive-like behaviour, cognitive deficits and abnormal social behaviour were less marked in FUS-tg-treated animals. Applied treatments have normalized protein expression of interleukin-1&#x3b2; (IL-1&#x3b2;) in the prefrontal cortex and the hippocampus, and of Iba-1 and GSK-3&#x3b2; in the hippocampus. Thus, the pre-symptomatic FUS[1-359]-tg mice demonstrate FTLD-like abnormalities that are attenuated by standard and new ALS treatments, including Neuro-Cell preparation.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Munter</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7583-1464</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babaevskaya</LastName><ForeName>Diana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-1692-0445</Identifier><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolters</LastName><ForeName>Erik Ch</ForeName><Initials>EC</Initials><Identifier Source="ORCID">0000-0003-4411-6892</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlov</LastName><ForeName>Dmitrii</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9120-7266</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Cognitive Dysfunctions, Institute of General Pathology and Pathophysiology, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Advanced Cell Technologies, Institute of Regenerative Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lysikova</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6521-3793</Identifier><AffiliationInfo><Affiliation>Institute of Physiologically Active Compounds, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V Kalueff</LastName><ForeName>Allan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7525-1950</Identifier><AffiliationInfo><Affiliation>Faculty of Biology, Ural Federal University, Ekaterinburg, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Translational Biomedicine and Institute of Experimental Medicine, St. Petersburg State University and Almazov Medical Research Center, St. Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorlova</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9345-7880</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oplatchikova</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7641-2330</Identifier><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomytkin</LastName><ForeName>Igor A</ForeName><Initials>IA</Initials><Identifier Source="ORCID">0000-0002-8426-3371</Identifier><AffiliationInfo><Affiliation>Department of Advanced Cell Technologies, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proshin</LastName><ForeName>Andrey</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7258-7870</Identifier><AffiliationInfo><Affiliation>PK Anokhin Research Institute of Normal Physiology, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umriukhin</LastName><ForeName>Aleksei</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1637-4245</Identifier><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PK Anokhin Research Institute of Normal Physiology, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesch</LastName><ForeName>Klaus-Peter</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0001-8348-153X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Molecular Psychiatry, Center of Mental Health, University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strekalova</LastName><ForeName>Tatyana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9937-5600</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Molecular Psychiatry, Center of Mental Health, University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cell Mol Med</MedlineTA><NlmUniqueID>101083777</NlmUniqueID><ISSNLinking>1582-1838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599551">FUS protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051546" MajorTopicYN="N">Cyclooxygenase 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FUS[1-359]-tg mice</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">animal model</Keyword><Keyword MajorTopicYN="N">celecoxib</Keyword><Keyword MajorTopicYN="N">emotionality and cognition</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">riluzole</Keyword><Keyword MajorTopicYN="N">stem cell therapy</Keyword></KeywordList><CoiStatement>There is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32667139</ArticleId><ArticleId IdType="pmc">PMC7520339</ArticleId><ArticleId IdType="doi">10.1111/jcmm.15628</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ito D, Suzuki N. Conjoint pathologic cascades mediated by ALS/FTLD&#x2010;U linked RNA&#x2010;binding proteins TDP&#x2010;43 and FUS. Neurology. 2011;77:1636&#x2010;1643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198978</ArticleId><ArticleId IdType="pubmed">21956718</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLoach A, Cozart M, Kiaei A, Kiaei M. A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies. Expert Opin Drug Discov. 2015;10:1099&#x2010;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">26307158</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiihashi G, Ito D, Arai I, et al. Dendritic homeostasis disruption in a novel frontotemporal dementia mouse model expressing cytoplasmic fused in sarcoma. E&#x2010;Biological Medicine. 2017;24:102&#x2010;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5652009</ArticleId><ArticleId IdType="pubmed">28928015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasey L, Hemangini JA, Dhaibar RD, et al. Severe respiratory changes at end stage in a FUS&#x2010;induced disease state in adult rats. BMC Neurosci. 2016;17:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5086065</ArticleId><ArticleId IdType="pubmed">27793099</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan M, Talbot K, Ansorge O. Pathogenesis of FUS&#x2010;associated ALS and FTD: insights from rodent models. Acta Neuropathol Commun. 2016;4:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5011941</ArticleId><ArticleId IdType="pubmed">27600654</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova TA, Peters OM, Deykin AV, et al. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J Biol Chem. 2013;288:25266&#x2010;25274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757190</ArticleId><ArticleId IdType="pubmed">23867462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lysikova EA, Kukharsky MS, Chaprov KD, et al. Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration. Genes Brain Behavior. 2019;22:12607.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437340</ArticleId></ArticleIdList></Reference><Reference><Citation>de Munter JPJM, Shafarevich I, Liundup A, et al. Neuro&#x2010;Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice. CNS Neurosci Ther. 2020;5:504&#x2010;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163689</ArticleId><ArticleId IdType="pubmed">31867846</ArticleId></ArticleIdList></Reference><Reference><Citation>Strekalova T, Steinbusch HW. Measuring behavior in mice with chronic stress depression paradigm. Prog Neuropsychoph Biol Psychiatry. 2010;34:348&#x2010;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">20026369</ArticleId></ArticleIdList></Reference><Reference><Citation>de Munter, JP , Beugels J, Munter S, et al. Standardized human bone marrow&#x2010;derived stem cells infusion improves survival and recovery in a rat model of spinal cord injury. J Neurol Sci. 2019;402:16&#x2010;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">31100652</ArticleId></ArticleIdList></Reference><Reference><Citation>Couch Y, Trofimov A, Markova N, et al. Low&#x2010;dose lipopolysaccharide (LPS) inhibits aggressive and augments depressive behaviours in a chronic mild stress model in mice. J Neuroinflammation. 2016;13:108&#x2010;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867526</ArticleId><ArticleId IdType="pubmed">27184538</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Dumont M, Banerjee R, et al. Behavioral deficits and progressive neuropathology in progranulin&#x2010;deficient mice: a mouse model of frontotemporal dementia. FASEB J. 2010;12:4639&#x2010;4647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfieri JA, Silva PR, Igaz LM. Early cognitive/social deficits and late motor phenotype in conditional wild&#x2010;type TDP&#x2010;43 transgenic mice. Front Aging Neurosci. 2016;8:310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5167738</ArticleId><ArticleId IdType="pubmed">28066234</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano AJ, Martens LH, Young AH, et al. Dissociation of frontotemporal dementia&#x2010;related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci. 2013;33:5352&#x2010;5361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoser BG, Blottner D. Matrix metalloproteinases MMP&#x2010;2, MMP&#x2010;7 and MMP&#x2010;9 in denervated human muscle. NeuroReport. 1999;13:2795&#x2010;2997.</Citation><ArticleIdList><ArticleId IdType="pubmed">10511442</ArticleId></ArticleIdList></Reference><Reference><Citation>Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res. 2007;85:2813&#x2010;2823.</Citation><ArticleIdList><ArticleId IdType="pubmed">17387691</ArticleId></ArticleIdList></Reference><Reference><Citation>Trofimov A, Strekalova T, Mortimer N, et al. Postnatal LPS challenge impacts escape learning and expression of plasticity factors Mmp9 and Timp1 in rats: effects of repeated training. Neurotox Res. 2017;32:175&#x2010;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5493723</ArticleId><ArticleId IdType="pubmed">28421528</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>